Deregulation of the Ras-Erk Signaling Axis Modulates the Enhancer Landscape

Cell Reports

Volumn 12, Issue 8, 2015, Pages 1300-1313

  Nabet, Behnam ^a   Ó Broin, Pilib ^b   Reyes, Jaime M ^c   Shieh, Kevin ^b   Lin, Charles Y ^c   Will, Christine M ^a   Popovic, Relja ^a   Ezponda, Teresa ^a   Bradner, James E ^c   Golden, Aaron A ^b,d   Licht, Jonathan D ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d YESHIVA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H3; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE C BETA; PROTEIN TYROSINE KINASE; RAF PROTEIN; RAS PROTEIN; SPROUTY PROTEIN; TRANSCRIPTION FACTOR GATA 4; GATA4 PROTEIN, MOUSE; HISTONE; KRAS2 PROTEIN, MOUSE; MEMBRANE PROTEIN; PHOSPHOPROTEIN; PROTEIN P21; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SPRY1 PROTEIN, MOUSE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENHANCER REGION; GENE DELETION; GENE EXPRESSION; HISTONE ACETYLATION; HISTONE MODIFICATION; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; ONCOGENE H RAS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPROUTY GENE; ACETYLATION; ANIMAL; CARCINOGENESIS; CELL LINE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PROTEIN PROCESSING;

ACETYLATION; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CARCINOGENESIS; CELL LINE; ENHANCER ELEMENTS, GENETIC; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GATA4 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; MAP KINASE SIGNALING SYSTEM; MEMBRANE PROTEINS; MICE; PHOSPHOPROTEINS; PROTEIN KINASE C BETA; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84939780724     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.06.078     Document Type: Article

References (46)

1. Agger K., Cloos P.A., Rudkjaer L., Williams K., Andersen G., Christensen J., Helin K. The H3K27me3 demethylase JMJD3 contributes to the activation of the INK4A-ARF locus in response to oncogene- and stress-induced senescence. Genes Dev. 2009, 23:1171-1176.
2. Akbulut S., Reddi A.L., Aggarwal P., Ambardekar C., Canciani B., Kim M.K., Hix L., Vilimas T., Mason J., Basson M.A., et al. Sprouty proteins inhibit receptor-mediated activation of phosphatidylinositol-specific phospholipase C. Mol. Biol. Cell 2010, 21:3487-3496.
3. Barradas M., Anderton E., Acosta J.C., Li S., Banito A., Rodriguez-Niedenführ M., Maertens G., Banck M., Zhou M.M., Walsh M.J., et al. Histone demethylase JMJD3 contributes to epigenetic control of INK4a/ARF by oncogenic RAS. Genes Dev. 2009, 23:1177-1182.
4. Barrett S.D., Bridges A.J., Dudley D.T., Saltiel A.R., Fergus J.H., Flamme C.M., Delaney A.M., Kaufman M., LePage S., Leopold W.R., et al. The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg. Med. Chem. Lett. 2008, 18:6501-6504.
5. Basson M.A., Akbulut S., Watson-Johnson J., Simon R., Carroll T.J., Shakya R., Gross I., Martin G.R., Lufkin T., McMahon A.P., et al. Sprouty1 is a critical regulator of GDNF/RET-mediated kidney induction. Dev. Cell 2005, 8:229-239.
6. Bowers E.M., Yan G., Mukherjee C., Orry A., Wang L., Holbert M.A., Crump N.T., Hazzalin C.A., Liszczak G., Yuan H., et al. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem. Biol. 2010, 17:471-482.
7. Brown J.D., Lin C.Y., Duan Q., Griffin G., Federation A.J., Paranal R.M., Bair S., Newton G., Lichtman A.H., Kung A.L., et al. NF-κB directs dynamic super enhancer formation in inflammation and atherogenesis. Mol. Cell 2014, 56:219-231.
8. Chapuy B., McKeown M.R., Lin C.Y., Monti S., Roemer M.G., Qi J., Rahl P.B., Sun H.H., Yeda K.T., Doench J.G., et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell 2013, 24:777-790.
9. Charlot C., Dubois-Pot H., Serchov T., Tourrette Y., Wasylyk B. A review of post-translational modifications and subcellular localization of Ets transcription factors: possible connection with cancer and involvement in the hypoxic response. Methods Mol. Biol. 2010, 647:3-30.
10. Chen Y.J., Wang Y.N., Chang W.C. ERK2-mediated C-terminal serine phosphorylation of p300 is vital to the regulation of epidermal growth factor-induced keratin 16 gene expression. J. Biol. Chem. 2007, 282:27215-27228.
11. Chen C., Liu Y., Rappaport A.R., Kitzing T., Schultz N., Zhao Z., Shroff A.S., Dickins R.A., Vakoc C.R., Bradner J.E., et al. MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia. Cancer Cell 2014, 25:652-665.
12. Cirillo L.A., Lin F.R., Cuesta I., Friedman D., Jarnik M., Zaret K.S. Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4. Mol. Cell 2002, 9:279-289.
13. Creyghton M.P., Cheng A.W., Welstead G.G., Kooistra T., Carey B.W., Steine E.J., Hanna J., Lodato M.A., Frampton G.M., Sharp P.A., et al. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc. Natl. Acad. Sci. USA 2010, 107:21931-21936.
14. De Craene B., Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat. Rev. Cancer 2013, 13:97-110.
15. De Raedt T., Beert E., Pasmant E., Luscan A., Brems H., Ortonne N., Helin K., Hornick J.L., Mautner V., Kehrer-Sawatzki H., et al. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature 2014, 514:247-251.
16. Edwin F., Anderson K., Ying C., Patel T.B. Intermolecular interactions of Sprouty proteins and their implications in development and disease. Mol. Pharmacol. 2009, 76:679-691.
17. Filippakopoulos P., Qi J., Picaud S., Shen Y., Smith W.B., Fedorov O., Morse E.M., Keates T., Hickman T.T., Felletar I., et al. Selective inhibition of BET bromodomains. Nature 2010, 468:1067-1073.
18. Garg V., Kathiriya I.S., Barnes R., Schluterman M.K., King I.N., Butler C.A., Rothrock C.R., Eapen R.S., Hirayama-Yamada K., Joo K., et al. GATA4 mutations cause human congenital heart defects and reveal an interaction with TBX5. Nature 2003, 424:443-447.
19. Göke J., Chan Y.S., Yan J., Vingron M., Ng H.H. Genome-wide kinase-chromatin interactions reveal the regulatory network of ERK signaling in human embryonic stem cells. Mol. Cell 2013, 50:844-855.
20. Hacohen N., Kramer S., Sutherland D., Hiromi Y., Krasnow M.A. sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways. Cell 1998, 92:253-263.
21. Heintzman N.D., Stuart R.K., Hon G., Fu Y., Ching C.W., Hawkins R.D., Barrera L.O., Van Calcar S., Qu C., Ching K.A., et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat. Genet. 2007, 39:311-318.
22. Herz H.M., Mohan M., Garruss A.S., Liang K., Takahashi Y.H., Mickey K., Voets O., Verrijzer C.P., Shilatifard A. Enhancer-associated H3K4 monomethylation by Trithorax-related, the Drosophila homolog of mammalian Mll3/Mll4. Genes Dev. 2012, 26:2604-2620.
23. Hu S., Xie Z., Onishi A., Yu X., Jiang L., Lin J., Rho H.S., Woodard C., Wang H., Jeong J.S., et al. Profiling the human protein-DNA interactome reveals ERK2 as a transcriptional repressor of interferon signaling. Cell 2009, 139:610-622.
24. Jirousek M.R., Gillig J.R., Gonzalez C.M., Heath W.F., McDonald J.H., Neel D.A., Rito C.J., Singh U., Stramm L.E., Melikian-Badalian A., et al. (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta. J. Med. Chem. 1996, 39:2664-2671.
25. Kaikkonen M.U., Spann N.J., Heinz S., Romanoski C.E., Allison K.A., Stender J.D., Chun H.B., Tough D.F., Prinjha R.K., Benner C., Glass C.K. Remodeling of the enhancer landscape during macrophage activation is coupled to enhancer transcription. Mol. Cell 2013, 51:310-325.
26. Kandoth C., McLellan M.D., Vandin F., Ye K., Niu B., Lu C., Xie M., Zhang Q., McMichael J.F., Wyczalkowski M.A., et al. Mutational landscape and significance across 12 major cancer types. Nature 2013, 502:333-339.
27. Laitinen J., Sistonen L., Alitalo K., Hölttä E. c-Ha-rasVal 12 oncogene-transformed NIH-3T3 fibroblasts display more decondensed nucleosomal organization than normal fibroblasts. J. Cell Biol. 1990, 111:9-17.
28. Liang Q., Wiese R.J., Bueno O.F., Dai Y.S., Markham B.E., Molkentin J.D. The transcription factor GATA4 is activated by extracellular signal-regulated kinase 1- and 2-mediated phosphorylation of serine 105 in cardiomyocytes. Mol. Cell. Biol. 2001, 21:7460-7469.
29. Lovén J., Hoke H.A., Lin C.Y., Lau A., Orlando D.A., Vakoc C.R., Bradner J.E., Lee T.I., Young R.A. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013, 153:320-334.
30. Martinez-Garcia E., Popovic R., Min D.J., Sweet S.M., Thomas P.M., Zamdborg L., Heffner A., Will C., Lamy L., Staudt L.M., et al. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood 2011, 117:211-220.
31. Masoumi-Moghaddam S., Amini A., Morris D.L. The developing story of Sprouty and cancer. Cancer Metastasis Rev. 2014, 33:695-720.
32. Mochly-Rosen D., Das K., Grimes K.V. Protein kinase C, an elusive therapeutic target?. Nat. Rev. Drug Discov. 2012, 11:937-957.
33. Ostuni R., Piccolo V., Barozzi I., Polletti S., Termanini A., Bonifacio S., Curina A., Prosperini E., Ghisletti S., Natoli G. Latent enhancers activated by stimulation in differentiated cells. Cell 2013, 152:157-171.
34. Rada-Iglesias A., Bajpai R., Swigut T., Brugmann S.A., Flynn R.A., Wysocka J. A unique chromatin signature uncovers early developmental enhancers in humans. Nature 2011, 470:279-283.
35. Schutzman J.L., Martin G.R. Sprouty genes function in suppression of prostate tumorigenesis. Proc. Natl. Acad. Sci. USA 2012, 109:20023-20028.
36. Shim K., Minowada G., Coling D.E., Martin G.R. Sprouty2, a mouse deafness gene, regulates cell fate decisions in the auditory sensory epithelium by antagonizing FGF signaling. Dev. Cell 2005, 8:553-564.
37. Shimamura T., Chen Z., Soucheray M., Carretero J., Kikuchi E., Tchaicha J.H., Gao Y., Cheng K.A., Cohoon T.J., Qi J., et al. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. Clin. Cancer Res. 2013, 19:6183-6192.
38. Smith E., Shilatifard A. Enhancer biology and enhanceropathies. Nat. Struct. Mol. Biol. 2014, 21:210-219.
39. Soloaga A., Thomson S., Wiggin G.R., Rampersaud N., Dyson M.H., Hazzalin C.A., Mahadevan L.C., Arthur J.S. MSK2 and MSK1 mediate the mitogen- and stress-induced phosphorylation of histone H3 and HMG-14. EMBO J. 2003, 22:2788-2797.
40. Spitz F., Furlong E.E. Transcription factors: from enhancer binding to developmental control. Nat. Rev. Genet. 2012, 13:613-626.
41. Stephen A.G., Esposito D., Bagni R.K., McCormick F. Dragging ras back in the ring. Cancer Cell 2014, 25:272-281.
42. Tee W.W., Shen S.S., Oksuz O., Narendra V., Reinberg D. Erk1/2 activity promotes chromatin features and RNAPII phosphorylation at developmental promoters in mouse ESCs. Cell 2014, 156:678-690.
43. Tie F., Banerjee R., Stratton C.A., Prasad-Sinha J., Stepanik V., Zlobin A., Diaz M.O., Scacheri P.C., Harte P.J. CBP-mediated acetylation of histone H3 lysine 27 antagonizes Drosophila Polycomb silencing. Development 2009, 136:3131-3141.
44. Turner N., Grose R. Fibroblast growth factor signalling: from development to cancer. Nat. Rev. Cancer 2010, 10:116-129.
45. Whyte W.A., Orlando D.A., Hnisz D., Abraham B.J., Lin C.Y., Kagey M.H., Rahl P.B., Lee T.I., Young R.A. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 2013, 153:307-319.
46. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 2009, 9:798-809.